<?xml version="1.0" encoding="UTF-8"?>
<p id="p0085">Induction of an inflammatory cytokine storm is a well-described phenomenon in patients with SARS,
 <xref rid="bib42" ref-type="bibr">
  <sup>42</sup>
 </xref> and it has been observed in early investigations of SARS-CoV-2 infection.
 <xref rid="bib43" ref-type="bibr">
  <sup>43</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib44" ref-type="bibr">
  <sup>44</sup>
 </xref> Consequently, the effects of immunomodulators on COVID-19 are being evaluated. Because interleukin 6 (IL-6) levels have been observed to be consistently elevated in patients with severe COVID-19,
 <xref rid="bib45" ref-type="bibr">45</xref>, 
 <xref rid="bib46" ref-type="bibr">46</xref>, 
 <xref rid="bib47" ref-type="bibr">47</xref>, 
 <xref rid="bib48" ref-type="bibr">48</xref> inhibition of the IL-6 receptor with monoclonal antibodies such as tocilizumab and sarilumab are of great interest for the treatment of COVID-19. Janus kinase (JAK) inhibitors such as baricitinib and ruxolitinib are also being considered for treating COVID-19â€“associated cytokine storm. Baricitinib was identified as a candidate COVID-19 therapeutic agent through search of a knowledge graph generated in part by machine learning.
 <xref rid="bib49" ref-type="bibr">
  <sup>49</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib50" ref-type="bibr">
  <sup>50</sup>
 </xref> However, there are concerns about drug-induced lymphocytopenia that may limit the utility of this small molecule targeted agent in the management of COVID-19.
 <xref rid="bib51" ref-type="bibr">
  <sup>51</sup>
 </xref> On the basis of previous reports of possible benefits, including decreased mortality and shorter hospital stay, of properly prescribed systemic glucocorticoid therapy for critically ill patients with SARS,
 <xref rid="bib52" ref-type="bibr">
  <sup>52</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib53" ref-type="bibr">
  <sup>53</sup>
 </xref> glucocorticoid management of COVID-19 is also being explored.
</p>
